Cellular Immunotherapies: Late Phase and Commercially Available Therapies Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

被引：0

作者：

Ortiz-Maldonado, Valentin ^{[1
]}

Martinez-Cibrian, Nuria ^{[2
]}

Del Campo Balguerias, Gonzalo ^{[3
]}

Espanol-Rego, Marta ^{[4
]}

Navarro, Sergio ^{[4
]}

Brillembourg, Helena ^{[5
]}

Alserawan, Leticia ^{[4
]}

Castella, Maria ^{[4
]}

Benitez-Ribas, Daniel ^{[4
]}

Magnano, Laura ^{[5
]}

Gonzalo Correa, Juan ^{[5
]}

Rivero, Andrea ^{[5
]}

Mozas, Pablo ^{[5
]}

Oliver-Caldes, Aina ^{[6
]}

Gine, Eva ^{[7
]}

Gerardo Rodriguez-Lobato, Luis ^{[5
]}

Martinez-Roca, Alexandra ^{[2
]}

Montoro-Lorite, Mercedes ^{[5
]}

Ayora, Pilar ^{[5
]}

Fernandez de larrea, Carlos ^{[5
]}

Pascal, Mariona ^{[4
]}

Esteve Reyner, Jordi ^{[5
]}

Urbano-Ispizua, Alvaro ^{[5
]}

Juan, Manel ^{[8
]}

Delgado, Julio ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Hosp Clin Barcelona, Barcelona, Spain

[3] Hosp Clin San Carlos, Dept Hematol, Madrid, Spain

[4] Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

[5] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[6] Univ Barcelona, Dept Hematol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[7] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[8] Hosp Clin Barcelona, Dept Immunol, Platform Immunotherapy Clin St Joan Deu, Barcelona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

705

引用

页数：4

共 50 条

[21] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
Phely, Laurent
Hensen, Luca
Faul, Christoph
Ruff, Christer Alexander
Schneider, Dina
Bethge, Wolfgang Andreas
Lengerke, Claudia
JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
[22] Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy
Gabelli, Maria
Oporto-Espuelas, Macarena
Burridge, Saskia
Chu, Jan
Farish, Susan
Hedges, Emma
Ware, Kirsty
Williams, Lindsey
Young, Lindsey
Alajangi, Rajesh
Ancliff, Philip
Bartram, Jack
Bonney, Denise
Chenchara, Lenka
Chiesa, Robert
Cugno, Chiara
Hodby, Katharine
Jalowiec, Katarzyna A.
Lazareva, Arina
Lucchini, Giovanna
Mirci-Danicar, Oana C.
Mullanfiroze, Khushnuma
Pavasovic, Vesna
Rao, Anupama
Rao, Kanchan
Riley, Lynne
Samarasinghe, Sujith
Shenton, Geoff
Silva, Juliana
Vora, Ajay
Hough, Rachael
Amrolia, Persis J.
Ghorashian, Sara
BLOOD ADVANCES, 2024, 8 (08) : 1959 - 1963
[23] Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.
Shah, Bijal D.
Ghobadi, Armin
Oluwole, Olalekan O.
Logan, Aaron
Boissel, Nicolas
Cassaday, Ryan Daniel
Forcade, Edouard
Bishop, Michael Russell
Topp, Max S.
Tzachanis, Dimitrios
O'Dwyer, Kristen M.
Arellano, Martha Lucia
Lin, Yi
Baer, Maria R.
Schiller, Gary J.
Zhou, Lang
Schuberth, Petra C.
Adhikary, Sabina
Masouleh, Behzad Kharabi
Houot, Roch
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
Perez, Arianne
Navale, Lynn
Rossi, John M.
Shen, Yueh-wei
Jiang, Yizhou
Sherman, Marika
Mardiros, Armen
Yoder, Sean C.
Go, William Y.
Rosenberg, Steven A.
Wiezorek, Jeff
Roberts, Margo R.
Chang, David D.
Kochenderfer, James N.
Bot, Adrian
BLOOD, 2015, 126 (23)
[25] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan
Qing Niu
Biping Deng
Shuangyou Liu
Tong Wu
Zhiyong Gao
Zhaoli Liu
Yue Zhang
Xiaomin Qu
Yanlei Zhang
Shaohui Liu
Zhuojun Ling
Yuehui Lin
Yongqiang Zhao
Yanzhi Song
Xiyou Tan
Yan Zhang
Zhihui Li
Zhichao Yin
Bingzhen Chen
Xinjian Yu
Ju Yan
Qinlong Zheng
Xuan Zhou
Jin Gao
Alex H. Chang
Xiaoming Feng
Chunrong Tong
Leukemia, 2019, 33 : 2854 - 2866
[26] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing, P.
Niu, Q.
Deng, B.
Liu, S.
Wu, T.
Gao, Z.
Chang, A. H.
Feng, X.
Tong, C.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1723 - 1723
[27] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Pan, Jing
Niu, Qing
Deng, Biping
Liu, Shuangyou
Wu, Tong
Gao, Zhiyong
Liu, Zhaoli
Zhang, Yue
Qu, Xiaomin
Zhang, Yanlei
Liu, Shaohui
Ling, Zhuojun
Lin, Yuehui
Zhao, Yongqiang
Song, Yanzhi
Tan, Xiyou
Zhang, Yan
Li, Zhihui
Yin, Zhichao
Chen, Bingzhen
Yu, Xinjian
Yan, Ju
Zheng, Qinlong
Zhou, Xuan
Gao, Jin
Chang, Alex H.
Feng, Xiaoming
Tong, Chunrong
LEUKEMIA, 2019, 33 (12) : 2854 - 2866
[28] Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients
Tu, Sanfang
Zhou, Lijuan
Huang, Rui
Zhou, Xuan
Yang, Jilong
He, Yanjie
Hu, Yuxing
Zhang, Honghao
Xie, Xiaoling
Li, Yuhua
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1437 - 1440
[29] Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis
Grover, Punita
Veilleux, Olivier
Tian, Lu
Sun, Ryan
Previtera, Melissa
Curran, Emily
Muffly, Lori
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S454 - S454
[30] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Chow, Victor A.
Shadman, Mazyar
Gopal, Ajay K.
BLOOD, 2018, 132 (08) : 777 - 781

← 1 2 3 4 5 →